Movement Alert|GENSCRIPT BIO Rises 4.18% in Regular Trading, Multiple Institutions Raise Target Prices Following Earnings Beat

Market Focus
Aug 19

On August 19, GENSCRIPT BIO rose 4.18% in regular trading, trading at 29.86 HKD/share, with turnover of HKD 359 million. The stock continued its post-earnings rally as multiple brokerages upgraded their outlooks.

On the news front, following the company's interim results released on August 16 that significantly beat expectations, Huatai Securities maintained a Buy rating with a target price of HKD 36.08, while CICC raised its target price by 78.8% to HKD 32.00, citing strong AIDD-driven life sciences business growth and improved operating efficiency.

The company reported H1 revenue of USD 404 million, up 27.3% year-over-year. The life sciences segment delivered adjusted operating profit of approximately USD 94 million, surging 102.8% YoY. AIDD-related business doubled year-over-year, maintaining rapid growth for three consecutive half-year periods. Adjusted net profit reached USD 62.5 million, up 203.3% YoY, driven by AI-powered drug discovery demand, CRDMO upstream recovery, and industrial enzyme expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10